Taken together, these results suggest that the combination of anti-IGF-1R therapies with bortezomib treatment could be beneficial for MM patients and may be particularly useful for the subpopulation of patients lacking CD45. This evidence concerns the gene PTPRC and Miyoshi myopathy.